Alimera Sciences, Inc. (ALIM)
Alimera Sciences, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Alpharetta, GA, US. The stock last traded at $5.54, down 0.18% on the session, giving a market capitalisation of $301.3M. On trailing twelve-month figures it carries a trailing P/E of -7.01, a net margin of -24.9%. Its beta of 1.25 implies it has historically moved more than the broad market.
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
Alimera Sciences, Inc. is most often compared with the following Healthcare names: